MCID: ACT165
MIFTS: 14

Acute Megakaryoblastic Leukemia Without Down Syndrome malady

Categories: Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Acute Megakaryoblastic Leukemia Without Down Syndrome

Aliases & Descriptions for Acute Megakaryoblastic Leukemia Without Down Syndrome:

Name: Acute Megakaryoblastic Leukemia Without Down Syndrome 56
Non-Ds-Amkl 56

Characteristics:

Orphanet epidemiological data:

56
acute megakaryoblastic leukemia without down syndrome
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:



External Ids:

Orphanet 56 ORPHA329469
ICD10 via Orphanet 34 C94.2

Summaries for Acute Megakaryoblastic Leukemia Without Down Syndrome

MalaCards based summary : Acute Megakaryoblastic Leukemia Without Down Syndrome, also known as non-ds-amkl, is related to invasive non-typhoidal salmonellosis. An important gene associated with Acute Megakaryoblastic Leukemia Without Down Syndrome is GLIS2 (GLIS Family Zinc Finger 2). The drugs Mitoxantrone and Daunorubicin have been mentioned in the context of this disorder.

Related Diseases for Acute Megakaryoblastic Leukemia Without Down Syndrome

Diseases related to Acute Megakaryoblastic Leukemia Without Down Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 invasive non-typhoidal salmonellosis 9.8 CBFA2T3 GLIS2

Symptoms & Phenotypes for Acute Megakaryoblastic Leukemia Without Down Syndrome

Drugs & Therapeutics for Acute Megakaryoblastic Leukemia Without Down Syndrome

Drugs for Acute Megakaryoblastic Leukemia Without Down Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
2
Daunorubicin Approved Phase 3 20830-81-3 30323
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
7
Thioguanine Approved Phase 3 154-42-7 2723601
8
Asparaginase Approved Phase 3 9015-68-3
9
leucovorin Approved, Nutraceutical Phase 3 58-05-9 54575, 6560146 143
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
11
Butyric Acid Experimental Phase 3 107-92-6 264
12 Analgesics Phase 3
13 Folic Acid Antagonists Phase 3
14 Gemtuzumab Phase 3
15 Cortisol succinate Phase 3
16 Topoisomerase Inhibitors Phase 3
17 Nucleic Acid Synthesis Inhibitors Phase 3
18 Dermatologic Agents Phase 3
19 Peripheral Nervous System Agents Phase 3
20 Vitamin B Complex Phase 3
21 Hydrocortisone 17-butyrate 21-propionate Phase 3
22 Hydrocortisone acetate Phase 3
23 Hydrocortisone-17-butyrate Phase 3
24 Anti-Bacterial Agents Phase 3
25 Etoposide phosphate Phase 3
26 Anti-Infective Agents Phase 3
27 Immunosuppressive Agents Phase 3
28 Anti-Inflammatory Agents Phase 3
29 Antimetabolites Phase 3
30 Antibiotics, Antitubercular Phase 3
31 Antimetabolites, Antineoplastic Phase 3
32 Antirheumatic Agents Phase 3
33 Antineoplastic Agents, Phytogenic Phase 3
34 Antiviral Agents Phase 3
35 Folate Nutraceutical Phase 3
36 Vitamin B9 Nutraceutical Phase 3
37
Coal tar Approved 8007-45-2

Interventional clinical trials:


id Name Status NCT ID Phase
1 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
2 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
3 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3
4 Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia Completed NCT01139307
5 Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial Completed NCT01507441
6 Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder Completed NCT01511575

Search NIH Clinical Center for Acute Megakaryoblastic Leukemia Without Down Syndrome

Genetic Tests for Acute Megakaryoblastic Leukemia Without Down Syndrome

Anatomical Context for Acute Megakaryoblastic Leukemia Without Down Syndrome

Publications for Acute Megakaryoblastic Leukemia Without Down Syndrome

Variations for Acute Megakaryoblastic Leukemia Without Down Syndrome

Expression for Acute Megakaryoblastic Leukemia Without Down Syndrome

Search GEO for disease gene expression data for Acute Megakaryoblastic Leukemia Without Down Syndrome.

Pathways for Acute Megakaryoblastic Leukemia Without Down Syndrome

GO Terms for Acute Megakaryoblastic Leukemia Without Down Syndrome

Biological processes related to Acute Megakaryoblastic Leukemia Without Down Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 8.96 CBFA2T3 GLIS2
2 negative regulation of transcription, DNA-templated GO:0045892 8.62 CBFA2T3 GLIS2

Sources for Acute Megakaryoblastic Leukemia Without Down Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....